ADC Therapeutics SA
NYSE:ADCT
P/E
Price to Earnings
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
Market Cap | P/E | ||||
---|---|---|---|---|---|
CH |
ADC Therapeutics SA
NYSE:ADCT
|
409.3m USD | -1.7 | ||
US |
Abbvie Inc
NYSE:ABBV
|
290.1B USD | 60.2 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
141.4B USD | 21 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.3B USD | 28 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.6B USD | 24.9 | ||
AU |
CSL Ltd
ASX:CSL
|
131.7B AUD | 34.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.4B USD | 14.7 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
39.5B USD | -8.4 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
27.8B USD | 24 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 60.8 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.